Q1 EPS Estimates for Nuvation Bio Increased by HC Wainwright

Nuvation Bio Inc. (NYSE:NUVB) – Equities researchers at HC Wainwright lifted their Q1 2026 EPS estimates for Nuvation Bio in a note issued to investors on Monday, January 12th. HC Wainwright analyst R. Burns now expects that the company will post earnings per share of ($0.11) for the quarter, up from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $17.00 price objective on the stock. The consensus estimate for Nuvation Bio’s current full-year earnings is ($0.36) per share. HC Wainwright also issued estimates for Nuvation Bio’s Q4 2026 earnings at ($0.06) EPS and FY2026 earnings at ($0.35) EPS.

Nuvation Bio (NYSE:NUVB) last released its earnings results on Monday, November 3rd. The company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Nuvation Bio had a negative return on equity of 54.99% and a negative net margin of 813.07%.The business had revenue of $13.12 million for the quarter, compared to the consensus estimate of $7.48 million.

Other equities research analysts also recently issued research reports about the company. Wedbush restated an “outperform” rating and set a $6.00 price target on shares of Nuvation Bio in a report on Monday, October 13th. Citigroup reaffirmed a “market outperform” rating on shares of Nuvation Bio in a report on Tuesday, November 4th. JMP Securities set a $10.00 price target on shares of Nuvation Bio in a report on Thursday, November 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Nuvation Bio in a report on Wednesday, October 8th. Finally, Truist Financial set a $11.00 target price on shares of Nuvation Bio in a research note on Monday, November 24th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Nuvation Bio currently has a consensus rating of “Moderate Buy” and a consensus target price of $10.40.

Nuvation Bio Stock Up 1.1%

NUVB stock opened at $6.53 on Wednesday. The firm has a market cap of $2.24 billion, a PE ratio of -10.21 and a beta of 1.54. The company has a debt-to-equity ratio of 0.14, a quick ratio of 8.39 and a current ratio of 8.48. Nuvation Bio has a one year low of $1.54 and a one year high of $9.75. The firm’s 50 day moving average price is $7.64 and its 200-day moving average price is $4.71.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the stock. Highline Wealth Partners LLC acquired a new stake in Nuvation Bio in the second quarter valued at about $25,000. Rangeley Capital LLC acquired a new stake in shares of Nuvation Bio in the 2nd quarter worth approximately $25,000. Parallel Advisors LLC increased its holdings in Nuvation Bio by 51.9% during the 3rd quarter. Parallel Advisors LLC now owns 7,597 shares of the company’s stock valued at $28,000 after acquiring an additional 2,597 shares in the last quarter. Cetera Investment Advisers acquired a new position in shares of Nuvation Bio in the second quarter worth $29,000. Finally, Captrust Financial Advisors purchased a new position in Nuvation Bio during the second quarter worth approximately $32,000. Institutional investors and hedge funds own 61.67% of the company’s stock.

Insider Buying and Selling

In other Nuvation Bio news, insider Dongfang Liu sold 150,000 shares of Nuvation Bio stock in a transaction on Monday, December 1st. The shares were sold at an average price of $7.82, for a total value of $1,173,000.00. Following the transaction, the insider directly owned 18,000 shares in the company, valued at approximately $140,760. The trade was a 89.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Gary Hattersley sold 100,000 shares of the stock in a transaction dated Monday, October 27th. The stock was sold at an average price of $5.02, for a total transaction of $502,000.00. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 320,000 shares of company stock valued at $2,050,800. 29.93% of the stock is owned by company insiders.

Nuvation Bio Company Profile

Nuvation Bio is a clinical-stage biotechnology company dedicated to discovering and developing small-molecule therapies for patients with cancer. The company employs an integrated research and development platform that spans target identification, preclinical evaluation, process chemistry, and early-stage clinical trials. By centralizing these capabilities, Nuvation Bio aims to accelerate the translation of promising drug candidates from laboratory research to first-in-human studies.

The company’s pipeline comprises multiple oncology programs, with small-molecule kinase inhibitors and targeted agents in Phase 1 development for both hematologic malignancies and solid tumors.